公开(公告)号：US20240131111A1

公开(公告)日：2024-04-25

申请号：US18537973

申请日：2023-12-13

Applicant: BioLineRx Ltd. ,  Biokine Therapeutics Ltd.

Inventor： Efrat HALBFINGER ,  Amnon PELED ,  Ella SORANI

IPC: A61K38/12 ,  A61P35/00

CPC classification number: A61K38/12 ,  A61P35/00

Abstract: A composition comprising BL-8040 (SEQ ID NO: 1) is disclosed herein, which may be for use in treating a condition treatable by BL-8040. The composition further comprises at least one compound characterized by a relative retention time of from 0.86 to 0.88 and/or a relative retention time of from 0.71 to 0.73 (wherein a relative retention time of BL-8040 is 1) under conditions described herein.

公开(公告)号：US11638743B2

公开(公告)日：2023-05-02

申请号：US16866599

申请日：2020-05-05

Applicant: Biokine Therapeutics Ltd. ,  BioLineRx Ltd.

Inventor： Amnon Peled ,  Yaron Pereg

IPC: A61K39/00 ,  C07K16/28 ,  A61K38/17 ,  A61K38/04 ,  A61K47/64 ,  A61P35/00 ,  A61K38/10 ,  A61K39/12 ,  A61K39/395 ,  C07K16/30

Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.

公开(公告)号：US10993985B2

公开(公告)日：2021-05-04

申请号：US16078696

申请日：2017-02-23

Applicant: BioLineRx Ltd. ,  Biokine Therapeutics Ltd.

Inventor： Yaron Pereg ,  Amnon Peled

IPC: A61K38/10 ,  A61K31/7068 ,  G01N33/569 ,  G01N33/574 ,  A61K45/06 ,  C07K7/08 ,  A61P35/02

Abstract: A method of treating acute myeloid leukemia (AML), including the steps of (i) measuring a density of blast cells in the peripheral blood and the bone marrow of a subject with AML; (ii) administering to the subject a CXCR4 antagonist; and (iii) administering to the subject a therapeutically effective amount of the CXCR4 antagonist and a therapeutically effective amount of a chemotherapeutic agent, if the blast cell density in the peripheral blood is less than 10% of the total peripheral white blood cells, or at least five-fold lower than the blast cell density in the bone marrow, or at least two-fold higher one day or more following step (ii).

公开(公告)号：US20200297807A1

公开(公告)日：2020-09-24

申请号：US16866605

申请日：2020-05-05

Applicant: Biokine Therapeutics Ltd. ,  BioLineRx Ltd.

Inventor： Amnon PELED ,  Yaron PEREG

IPC: A61K38/17 ,  A61K38/04 ,  A61K47/64 ,  A61P35/00 ,  A61K38/10 ,  A61K39/12 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30

Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.

公开(公告)号：US20200297802A1

公开(公告)日：2020-09-24

申请号：US16866592

申请日：2020-05-05

Applicant: Biokine Therapeutics Ltd. ,  BioLineRx Ltd.

Inventor： Amnon PELED ,  Yaron PEREG

IPC: A61K38/17 ,  A61K38/04 ,  A61K47/64 ,  A61P35/00 ,  A61K38/10 ,  A61K39/12 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30

Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an MO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.

公开(公告)号：US20170226157A1

公开(公告)日：2017-08-10

申请号：US15326512

申请日：2015-12-09

Applicant: Biokine Therapeutics Ltd.

Inventor： Amnon PELED

IPC: C07K7/08 ,  C07K16/00

CPC classification number: C07K7/08 ,  C07K14/7158 ,  C07K16/00 ,  C07K2319/02 ,  C07K2319/30

Abstract: Use of a polypeptide comprising a chemokine binding peptide as set forth in SEQ ID NO: 1 attached to an Fc domain or a fragment thereof is provided. The polypeptide is used in the manufacture of a medicament identified for the treatment of an ocular disease in a subject in need thereof.

公开(公告)号：US20160082071A1

公开(公告)日：2016-03-24

申请号：US14771513

申请日：2014-03-19

Applicant: BIOKINE THERAPEUTICS LTD. ,  BIOLINERX LTD.

Inventor： Amnon PELED ,  Yaron PEREG

IPC: A61K38/10 ,  A61K9/00 ,  A61K31/7068

CPC classification number: A61K38/10 ,  A61K9/0019 ,  A61K31/7068 ,  A61K45/06 ,  A61K2300/00

Abstract: There is provided a method of treating a myeloid leukemia. The method includes the step of administering to a subject in need thereof a therapeutically effective amount of a CXCR4-antagonistic peptide and a therapeutically effective amount of a chemotherapeutic agent.

Abstract translation: 提供了治疗骨髓性白血病的方法。 该方法包括向有需要的受试者施用治疗有效量的CXCR4拮抗肽和治疗有效量的化学治疗剂的步骤。

公开(公告)号：US20140030211A1

公开(公告)日：2014-01-30

申请号：US13889442

申请日：2013-05-08

Applicant: Biokine Therapeutics Ltd.

Inventor： Amnon PELED ,  Michal Begin ,  Katia Beider ,  Michal Abraham

IPC: A61K38/10 ,  A61K38/19

CPC classification number: A61K38/10 ,  A61K35/28 ,  A61K38/193 ,  A61K2300/00

Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for providing improved bone marrow transplantation and in the treatment of other conditions wherein bone marrow depletion or suppression is involved.

Abstract translation: 本发明涉及T-140类似物的新颖治疗用途及其组合物。 具体地，本发明提供了可用于提供改进的骨髓移植和涉及其中涉及骨髓消耗或抑制的其它病症的治疗的组合物和方法。

公开(公告)号：US11596666B2

公开(公告)日：2023-03-07

申请号：US16866606

申请日：2020-05-05

Applicant: Biokine Therapeutics Ltd. ,  BioLineRx Ltd.

Inventor： Amnon Peled ,  Yaron Pereg

IPC: A61K39/00 ,  C07K16/28 ,  A61K38/17 ,  A61K38/04 ,  A61K47/64 ,  A61P35/00 ,  A61K38/10 ,  A61K39/12 ,  A61K39/395 ,  C07K16/30

Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.

公开(公告)号：US10959979B2

公开(公告)日：2021-03-30

申请号：US16868558

申请日：2020-05-07

Applicant: Biokine Therapeutics Ltd.

Inventor： Amnon Peled ,  Michal Abraham Karni ,  Orly Eizenberg

IPC: A61K31/352 ,  C07D311/76 ,  C07D215/26 ,  C07D401/12 ,  C07D471/04 ,  C07D405/12 ,  A61K31/192 ,  A61K45/06 ,  A61K31/341 ,  A61K31/167 ,  A61K31/366 ,  A61K31/661 ,  A61K31/37 ,  A61P35/00

Abstract: Compounds capable of, or usable in, killing cancer cells, and/or modulating a biological activity of a chemokine, and/or inhibiting a kinase, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or treating disease and disorders such as cancer and inflammatory diseases and disorders, are provided herein. The compounds are listed in Tables 2, 4 and 5, and/or are represented by Formulae I, IV, V and VI, as defined in the specification. Methods utilizing these compounds are also provided.